<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03961165</url>
  </required_header>
  <id_info>
    <org_study_id>2018/2380</org_study_id>
    <nct_id>NCT03961165</nct_id>
  </id_info>
  <brief_title>BUSCLAB - Buscopan to Prevent Slow Progress in Labor</brief_title>
  <official_title>BUSCLAB - A Double Blind Randomized Placebo-Controlled Trial Investigating the Effect of Intravenous Butylscopolamine Bromide to Prevent Slow Progress in Labor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effect of Butylscopolamine Bromide on duration of the active phase of first
      stage of labor in first time mothers who cross the alert-line for labor dystocia, according
      to the WHO partograph.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of labor from the time when the participant was given IMP to delivery</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Time to event variable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration from when the participant was given IMP, to 10 cm dilatation</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Time to event variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean cervical dilatation rate, calculated as mean cervical dilatation from IMP is given to 10 cm</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Continuous variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of labor from the onset of active labor (at least 3 cm dilatation) to delivery</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Time to event variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spontaneous vaginal delivery vs operative delivery (vacuum, forceps or cesarean delivery)</measure>
    <time_frame>At birth</time_frame>
    <description>Categorical variable, fraction of all deliveries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal delivery vs cesarean delivery</measure>
    <time_frame>At birth</time_frame>
    <description>Categorical variable, fraction of all deliveries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spontaneous vaginal delivery, vacuum delivery, forceps delivery, or emergency cesarean delivery</measure>
    <time_frame>At birth</time_frame>
    <description>Categorical variable, fraction of all deliveries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of oxytocin given, measured 1. As total time with treatment</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Continuous variable, minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of oxytocin given, measured 2. As International Units (IU)</measure>
    <time_frame>At birth</time_frame>
    <description>Continuous variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores using a Visual Analogue Scale at baseline and 30 minutes after administration of IMP</measure>
    <time_frame>up to 30 minutes</time_frame>
    <description>Continuous variable, scale 1 to 9, where 9 is most severe pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum hemorrhage (mL)</measure>
    <time_frame>2 hours after birth</time_frame>
    <description>Continuous variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary retention, defined as need for urinary catheter before the participants leave the delivery ward</measure>
    <time_frame>24 hours after birth</time_frame>
    <description>Categorical variable, fraction of women with urinary retention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anal sphincter injury</measure>
    <time_frame>At birth</time_frame>
    <description>Categorical variable, fraction of all deliveries and fraction of all vaginal deliveries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar score at 5 minutes and 10 minutes after delivery</measure>
    <time_frame>5 and 10 minutes after birth</time_frame>
    <description>Ordinal variable, score 0 to 10 where 10 is highest score indicating most vital neonate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH levels in umbilical vein and artery after delivery</measure>
    <time_frame>At birth</time_frame>
    <description>Continuous variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to the Neonatal Intensive Care Unit</measure>
    <time_frame>Within 2 hours after birth</time_frame>
    <description>Categorical variable, fraction of deliveries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth experience measured by the validated questionnaire Child Birth Experience Questionnaire</measure>
    <time_frame>4 weeks after birth</time_frame>
    <description>Continuous variable for each category</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Labor (Obstetrics)--Complications</condition>
  <condition>Labor; Prolonged, First Stage</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mL 20 mg/mL butylscopolamine bromide i.v.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1mL 9mg/mL NaCl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Butylscopolamine Bromide 20 MG/ML</intervention_name>
    <description>1 mL Butylscopolamine Bromide 20 mg/mL i.v. Single dose.</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride 9mg/mL</intervention_name>
    <description>1 mL Sodium Chloride 9 mg/mL i.v. Single dose.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years

          -  Primiparous women

          -  Spontaneous onset of labor

          -  Active phase of labor

          -  ≥37 weeks of gestation

          -  Vertex position

          -  Crossing the alert line, i.e. cervical dilatation of less than one cm per hour in the
             active phase of first stage of labour (cervix dilation ≥3 - &lt;10 cm)

          -  Signed informed consent and expected cooperation of the patients for the treatment and
             follow up must be obtained and documented according to ICH GCP and national and local
             regulations

        Exclusion Criteria:

          -  Multiple gestation

          -  Elective cesarean section

          -  Women in labor already receiving oxytocin when crossing the alert line

          -  Fully dilated cervix when crossing the alert line

          -  Preeclampsia defined as blood pressure ≥140/90 and proteinuria (1 or more on a urine
             dipstick on more than one occasion) with debut after 20 weeks of pregnancy

          -  Known intestinal stenosis, ileus or megacolon

          -  Persisting maternal tachycardia (heart rate &gt;130 beats per minute)

          -  Known maternal myasthenia gravis

          -  Persisting fetal tachycardia (fetal heart rate baseline &gt;170 beats per minute)

          -  Hypersensitivity to any of the ingredients in IMP or placebo (butylscopolamine bromide
             or sodium chloride)

          -  Women with heart disease who are under surveillance with heart rate monitoring during
             labor

          -  Known fetal heart disease

          -  Untreated glaucoma
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Trond M Michelsen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trond M Michelsen, MD, PhD</last_name>
    <phone>+4723070000</phone>
    <email>trmi1@ous-hf.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oslo University Hospital Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trond M Michelsen, MD, PhD</last_name>
      <phone>+472307000</phone>
      <email>trmi1@ous-hf.no</email>
    </contact>
    <contact_backup>
      <last_name>Lise C Gaudernack, MPH</last_name>
      <phone>+4723072640</phone>
      <email>lisgau@ous-hf.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>May 27, 2019</last_update_submitted>
  <last_update_submitted_qc>May 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Trond Melbye Michelsen</investigator_full_name>
    <investigator_title>Attending Physician</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scopolamine</mesh_term>
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

